Notably, the TP10 clinical trial in PGD showed no increase in infection risk following acute C3 inhibition, and recent clinical use of pegcetacoplan in kidney xenotransplantation helps to further assuage these concerns (125, 153). This evidence concerns the gene C3 and infection.